gefitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	1282	184475-35-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ZD1839 gefitinib iressa ZD 1839	Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation. Molecular weight: 446.91 Formula: C22H24ClFN4O3 CLOGP: 5.25 LIPINSKI: 1 HAC: 7 HDO: 1 TPSA: 68.74 ALOGS: -4.22 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ZD1839
gefitinib
iressa
ZD 1839

Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation.

Molecular weight: 446.91
Formula: C22H24ClFN4O3
CLOGP: 5.25
LIPINSKI: 1
HAC: 7
HDO: 1
TPSA: 68.74
ALOGS: -4.22
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	8 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	34 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 5, 2003	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1178.77	23.83	410	6511	81711	63400390
Drug resistance	730.58	23.83	211	6710	22722	63459379
Acquired gene mutation	429.99	23.83	77	6844	906	63481195
Metastases to central nervous system	310.01	23.83	96	6825	13009	63469092
EGFR gene mutation	288.10	23.83	46	6875	251	63481850
Interstitial lung disease	253.53	23.83	127	6794	61781	63420320
Hepatic function abnormal	238.35	23.83	104	6817	37038	63445063
Disease progression	191.49	23.83	135	6786	122623	63359478
Malignant transformation	184.51	23.83	33	6888	384	63481717
Liver disorder	173.40	23.83	94	6827	53593	63428508
Diarrhoea	146.03	23.83	270	6651	715096	62767005
Paronychia	145.24	23.83	44	6877	5521	63476580
Metastases to meninges	124.33	23.83	33	6888	2569	63479532
Lung disorder	102.77	23.83	71	6850	62190	63419911
Dermatitis acneiform	86.88	23.83	29	6892	4967	63477134
Gene mutation	74.25	23.83	20	6901	1645	63480456
Metastases to lung	69.83	23.83	32	6889	12718	63469383
Metastases to bone	68.31	23.83	37	6884	20982	63461119
Pleural effusion	64.15	23.83	64	6857	93146	63388955
Small cell lung cancer	60.54	23.83	17	6904	1632	63480469
Skin toxicity	53.77	23.83	20	6901	4694	63477407
Metastases to liver	43.83	23.83	29	6892	23610	63458491
Hepatotoxicity	42.55	23.83	34	6887	37007	63445094
Rash	40.13	23.83	143	6778	560728	62921373
Therapy partial responder	38.10	23.83	20	6901	10638	63471463
Skin disorder	38.04	23.83	29	6892	29478	63452623
Arthralgia	32.25	23.83	11	6910	569699	62912402
Metastasis	31.48	23.83	14	6907	5183	63476918
Leukoencephalopathy	30.35	23.83	13	6908	4400	63477701
Pneumothorax	30.26	23.83	20	6901	16241	63465860
Dry skin	28.42	23.83	33	6888	56854	63425247
Lymphangiosis carcinomatosa	27.57	23.83	9	6912	1436	63480665
PRIDE syndrome	26.06	23.83	4	6917	16	63482085
Carcinoembryonic antigen increased	25.81	23.83	9	6912	1756	63480345
Pneumonitis	25.71	23.83	25	6896	35197	63446904
Neoplasm progression	25.00	23.83	25	6896	36403	63445698
Hepatitis	24.93	23.83	26	6895	39762	63442339
Sarcomatoid carcinoma	24.06	23.83	4	6917	29	63482072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	482.14	24.00	240	4827	87806	34864058
Interstitial lung disease	289.97	24.00	155	4912	65127	34886737
Drug resistance	273.12	24.00	112	4955	25815	34926049
Acquired gene mutation	210.87	24.00	47	5020	1308	34950556
EGFR gene mutation	182.04	24.00	30	5037	147	34951717
Lung disorder	155.33	24.00	83	4984	34613	34917251
Metastases to central nervous system	123.53	24.00	46	5021	8159	34943705
Disease progression	103.62	24.00	101	4966	107976	34843888
Rash	92.93	24.00	136	4931	222616	34729248
Metastases to bone	78.07	24.00	37	5030	11933	34939931
Hepatic function abnormal	65.44	24.00	53	5014	44310	34907554
Metastases to meninges	57.87	24.00	17	5050	1437	34950427
Diarrhoea	56.82	24.00	153	4914	389759	34562105
Dermatitis acneiform	52.56	24.00	23	5044	6166	34945698
Malignant transformation	52.39	24.00	14	5053	837	34951027
Mitochondrial aspartate aminotransferase increased	50.03	24.00	7	5060	7	34951857
Metastases to lung	49.36	24.00	25	5042	9295	34942569
Metastases to liver	48.22	24.00	28	5039	13635	34938229
Metastases to pleura	45.10	24.00	11	5056	455	34951409
Liver disorder	41.54	24.00	36	5031	32961	34918903
Lymphangiosis carcinomatosa	37.54	24.00	11	5056	921	34950943
Paronychia	30.03	24.00	13	5054	3392	34948472
Dehydration	28.51	24.00	60	5007	129909	34821955
Vomiting	28.00	24.00	89	4978	247532	34704332
Decreased appetite	24.73	24.00	66	5001	166326	34785538
Malignant pleural effusion	24.53	24.00	9	5058	1527	34950337

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1253.70	22.18	521	10217	135469	79598181
Drug resistance	887.62	22.18	297	10441	41916	79691734
Acquired gene mutation	587.69	22.18	118	10620	2115	79731535
Interstitial lung disease	468.42	22.18	250	10488	112350	79621300
EGFR gene mutation	442.94	22.18	73	10665	391	79733259
Metastases to central nervous system	366.48	22.18	121	10617	16254	79717396
Hepatic function abnormal	285.87	22.18	156	10582	72951	79660699
Lung disorder	214.42	22.18	134	10604	80423	79653227
Malignant transformation	202.30	22.18	44	10694	1174	79732476
Liver disorder	201.68	22.18	124	10614	72293	79661357
Disease progression	169.47	22.18	163	10575	184199	79549451
Diarrhoea	164.58	22.18	363	10375	880126	78853524
Metastases to meninges	150.43	22.18	43	10695	3558	79730092
Paronychia	144.26	22.18	50	10688	7758	79725892
Metastases to bone	141.45	22.18	68	10670	24359	79709291
Dermatitis acneiform	128.61	22.18	49	10689	9944	79723706
Rash	125.62	22.18	254	10484	578104	79155546
Metastases to lung	94.46	22.18	47	10691	18116	79715534
Pleural effusion	73.38	22.18	94	10644	145168	79588482
Gene mutation	72.89	22.18	23	10715	2663	79730987
Small cell lung cancer	71.32	22.18	23	10715	2857	79730793
Metastases to liver	67.51	22.18	44	10694	28270	79705380
Lymphangiosis carcinomatosa	60.77	22.18	19	10719	2135	79731515
Skin toxicity	60.09	22.18	27	10711	8287	79725363
Mitochondrial aspartate aminotransferase increased	50.54	22.18	7	10731	7	79733643
Hepatotoxicity	50.06	22.18	47	10691	51305	79682345
Metastasis	48.63	22.18	22	10716	6858	79726792
Skin disorder	45.00	22.18	37	10701	33906	79699744
Malignant pleural effusion	41.42	22.18	16	10722	3364	79730286
Therapy partial responder	41.38	22.18	27	10711	17370	79716280
Metastases to pleura	40.90	22.18	13	10725	1541	79732109
Decreased appetite	40.19	22.18	119	10619	342299	79391351
Cystitis haemorrhagic	39.76	22.18	21	10717	9151	79724499
Arthralgia	39.32	22.18	14	10724	571789	79161861
Metastases to lymph nodes	37.29	22.18	21	10717	10376	79723274
Leukoencephalopathy	36.78	22.18	19	10719	7910	79725740
Pneumothorax	35.72	22.18	30	10708	28293	79705357
Dehydration	32.73	22.18	90	10648	248097	79485553
PRIDE syndrome	32.39	22.18	5	10733	16	79733634
Alanine aminotransferase increased	29.93	22.18	67	10671	162503	79571147
Carcinoembryonic antigen increased	29.02	22.18	11	10727	2198	79731452
Pneumatosis intestinalis	28.73	22.18	15	10723	6382	79727268
Respiratory failure	28.35	22.18	70	10668	180841	79552809
Dry skin	28.18	22.18	40	10698	67955	79665695
Drug hypersensitivity	27.08	22.18	4	10734	298912	79434738
Lung infiltration	26.31	22.18	23	10715	22889	79710761
Pain	25.07	22.18	35	10703	703767	79029883
Pneumonia	24.97	22.18	163	10575	660083	79073567
Pneumonitis	24.04	22.18	35	10703	60825	79672825
Cerebral infarction	23.72	22.18	30	10708	45646	79688004
Peripheral swelling	23.53	22.18	4	10734	269613	79464037
Lung carcinoma cell type unspecified recurrent	23.43	22.18	6	10732	327	79733323
Radiation pneumonitis	22.90	22.18	11	10727	3922	79729728
Pulmonary embolism	22.36	22.18	62	10676	171592	79562058

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EB01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:74440	EGFR antagonoists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer	indication	254637007	DOID:3908
Non-small cell lung cancer, positive for epidermal growth factor receptor expression	indication	426964009
Fibrosis of lung	contraindication	51615001	DOID:3770
Acute nephropathy	contraindication	58574008
Interstitial pneumonia	contraindication	64667001
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Non-small cell lung cancer, negative for epidermal growth factor receptor expression	contraindication	427038005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.65	Basic
pKa2	5.8	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Ki	9.40	CHEMBL	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.96	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	6.64	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	5.74	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	6.20	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN		IC50	5.70	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	6	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		IC50	5.77	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN		IC50	5.72	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		Kd	5.96	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	5.57	CHEMBL
Death-associated protein kinase 3	Kinase	O43293	DAPK3_HUMAN		Kd	5.24	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.36	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN		Kd	6.39	CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	5.64	CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle	Kinase	Q9H1R3	MYLK2_HUMAN		Kd	5.72	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN		Kd	5.74	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.46	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		Kd	6	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.43	CHEMBL
Serine/threonine-protein kinase 17B	Kinase	O94768	ST17B_HUMAN		Kd	5.42	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	6.33	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	5.80	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	5.70	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	6.23	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	5.16	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	6.37	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	5.59	CHEMBL
Serine/threonine-protein kinase 36	Kinase	Q9NRP7	STK36_HUMAN		Kd	5.24	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	5.26	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	5.70	CHEMBL
Beta-secretase 1	Enzyme	P56817	BACE1_HUMAN		IC50	4.70	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	8.15	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	6.28	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN		Kd	5.89	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		IC50	5.64	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	6.04	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	6.44	CHEMBL
Mitogen-activated protein kinase 9	Kinase	P45984	MK09_HUMAN		Kd	5.85	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	5.60	CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Kinase	Q8TBX8	PI42C_HUMAN		Kd	5.12	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN		IC50	6.01	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	5.74	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	6.21	CHEMBL
Serine/threonine-protein kinase D1	Kinase	Q15139	KPCD1_HUMAN		Kd	5.46	CHEMBL
Serine/threonine-protein kinase DCLK3	Kinase	Q9C098	DCLK3_HUMAN		Kd	5.54	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	5.34	CHEMBL
Casein kinase I isoform delta	Kinase	P48730	KC1D_HUMAN		Kd	5.49	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.22	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	6.54	CHEMBL
Serine/threonine-protein kinase NLK	Kinase	Q9UBE8	NLK_HUMAN		Kd	5.38	CHEMBL
Interleukin-1 receptor-associated kinase 3	Kinase	Q9Y616	IRAK3_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	5.68	CHEMBL
Myotonin-protein kinase	Kinase	Q09013	DMPK_HUMAN		Kd	5.16	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	5.26	CHEMBL
Serine/threonine-protein kinase pim-3	Kinase	Q86V86	PIM3_HUMAN		Kd	5.24	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	5.92	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.89	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	5.40	CHEMBL
Mitogen-activated protein kinase 6	Kinase	Q16659	MK06_HUMAN		Kd	5.80	CHEMBL
Mitogen-activated protein kinase 4	Kinase	P31152	MK04_HUMAN		Kd	5.51	CHEMBL
Ribosomal protein S6 kinase alpha-4	Kinase	O75676	KS6A4_HUMAN		Kd	5.92	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	5.74	CHEMBL
Interleukin-1 receptor-associated kinase 4	Kinase	Q9NWZ3	IRAK4_HUMAN		Kd	6.27	CHEMBL
Serine/threonine-protein kinase Chk2	Kinase	O96017	CHK2_HUMAN		Kd	6.10	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.49	CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	6.51	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	7.16	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	5.48	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	5.68	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.62	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN		Kd	6.10	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	6.25	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	6.22	CHEMBL
Ferrochelatase, mitochondrial	Enzyme	P22830	HEMH_HUMAN		Kd	5.17	CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		Kd	5.57	CHEMBL
Acyl-CoA dehydrogenase family member 10	Enzyme	Q6JQN1	ACD10_HUMAN		Kd	4.47	CHEMBL
Transcription factor p65	Transcription factor	Q04206	TF65_HUMAN		IC50	7.26	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.70	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN		Kd	5.42	SCIENTIFIC LITERATURE
Serine/threonine-protein kinase ULK3	Kinase		ULK3_MOUSE		Kd	5.85	CHEMBL
Tubulin alpha-1A chain	Structural		TBA1A_RAT		Kd	6.39	CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	4.06	CHEMBL
Quinolone resistance protein NorA	Transporter		NORA_STAAU		IC50	5.01	CHEMBL

External reference:

ID	Source
4021392	VUID
N0000148810	NUI
D01977	KEGG_DRUG
4021392	VANDF
C1122962	UMLSCUI
CHEBI:49668	CHEBI
IRE	PDB_CHEM_ID
CHEMBL939	ChEMBL_ID
D000077156	MESH_DESCRIPTOR_UI
DB00317	DRUGBANK_ID
4941	IUPHAR_LIGAND_ID
8204	INN_ID
S65743JHBS	UNII
123631	PUBCHEM_CID
281883	RXNORM
17257	MMSL
256478	MMSL
46712	MMSL
d04868	MMSL
009981	NDDF
398685009	SNOMEDCT_US
407100002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
IRESSA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0482	TABLET, COATED	250 mg	ORAL	NDA	28 sections
IRESSA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0482	TABLET, COATED	250 mg	ORAL	NDA	28 sections
IRESSA	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0482	TABLET, COATED	250 mg	ORAL	NDA	28 sections
Gefitinib	HUMAN PRESCRIPTION DRUG LABEL	1	0480-4053	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Gefitinib	HUMAN PRESCRIPTION DRUG LABEL	1	50742-366	TABLET, COATED	250 mg	ORAL	ANDA	26 sections
Gefitinib	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4512	TABLET	250 mg	ORAL	ANDA	26 sections
Gefitinib	HUMAN PRESCRIPTION DRUG LABEL	1	67184-0531	TABLET, COATED	250 mg	ORAL	ANDA	26 sections
Gefitinib	Human Prescription Drug Label	1	69339-168	TABLET, FILM COATED	250 mg	ORAL	ANDA	25 sections